Laboratoires Thea   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Clermont-Ferrand France (1993)
Status: No NME R&D (1993)

Organization Overview

First Clinical Trial
2001
NCT00357019
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

anheront@gmail.com | Laboratoires Thea | Laboratorios Thea, Spain

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bacterial Infections (Phase 1)

Blepharitis (Phase 2)

Capsule Opacification (Phase 4)

Cataract (Phase 4)

Conjunctivitis (Phase 4)

Conjunctivitis, Allergic (Phase 4)

Conjunctivitis, Bacterial (Phase 3)

Dry Eye Syndromes (Phase 4)

Eye Infections (Phase 1)

Eye Infections, Bacterial (Phase 1)

Glaucoma (Phase 4)

Glaucoma, Open-Angle (Phase 4)

Hypertension (Phase 4)

Keratoconjunctivitis (Phase 4)

Keratoconjunctivitis Sicca (Phase 4)

Ocular Hypertension (Phase 4)

Trachoma (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial APIs: 32